CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 54 enrolled
Drug / intervention
Oral Fosmanogepix +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06961708
NCT06961708Phase 1Completed

A Phase 1, Randomized, Single-center, Double-blind, Placebo-controlled Study of Fosmanogepix Administered as Single and Multiple Doses in Healthy Adult Chinese Subjects

Basilea Pharmaceutica·interventional·Posted May 8, 2025·Updated Apr 6, 2026

In Brief

A Phase 1 clinical trial evaluating Oral Fosmanogepix, IV Fosmanogepix, and 2 other interventions for Healthy. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of this study was to investigate the pharmacokinetics and safety of the investigational drug fosmanogepix including its active moiety manogepix following a single dose and multiple doses (by intravenous infusion (IV) or orally) in healthy Chinese adults. The study consisted of 2 consecutive Parts (Part-1, single-dose part followed by Part-2, multiple-dose part) including a total of 54 subjects (32 subjects in Part-1 and 22 subjects in PART-2) randomized.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina

Timeline

Phase 1CompletedFinished
2026
First PostedMay 8, 2025
Enrollment StartApr 14, 2025
Primary CompletionJul 15, 2025
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 1.2 years ago

Interventions

Oral Fosmanogepixdrug

Oral Tablet

IV Fosmanogepixdrug

IV infusion

IV placebodrug

Matching IV placebo

oral placebodrug

Matching oral placebo